Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study
Frontiers in Public Health · 18.11.2026 · 14
DOI: 10.3389/fpubh.2026.1920752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 18.11.2026. Verfasst von José Francisco Barbas del Buey und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Nirsevimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), is effective in preventing hospitalizations during infants' first RSV season, but concerns about long-term effects persist. Long-term studies show no significant differences in second-season events between immunized and non-immunized infants.
Methods
A self-controlled case series study tracked hospital admissions for newborns born between April 1, 2023, and March 31, 2024, from October 1, 2023, to September 30, 2025. It compared events between RSV seasons for infants immunized with nirsevimab in their first RSV season.
Results
A total of 1,152 RSV-associated hospitalizations were analyzed, involving 1,128 participants. Cases among immunized participants -crude data- rose by 3.42 times (95% CI: 2.84 to 4.14) during the second RSV season (503 vs 147). In the adjusted and self-controlled model, the hospitalization rate during the second season is 7.99 times higher than during nirsevimab's effectiveness period (95% CI: 5.80 to 11.02). Similarly, PICU admissions increased by 2.14-fold (95% CI: 0.87 to 5.30), although low statistical power limits conclusiveness. No lingering effect from the immunization was observed during the second season. The risk of hospitalizations, considering their age, during peak periods in the second season was 4.31 to 12.53 times higher than during the nirsevimab protection period. No significant differences were noted for PICU admissions.
Discussion
No evidence of nirsevimab residual efficacy was observed during the second RSV season. The age-related reduction in hospitalization risk among the immunized did not prevent the increase in disease burden in the second year of life. This contradicts earlier evidence and therefore necessitates a reevaluation of policies and preventive measures.
Zitieren
APA
Buey, J. F. B. D., García, M. A., Martínez, J. I., Cofiño, M. E. H., Montalvo, M. M., Bueno, S. J., & Arnáez, A. A. (2026). Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1920752
Vancouver
Buey JFBD, García MA, Martínez JI, Cofiño MEH, Montalvo MM, Bueno SJ, et al. Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1920752
BibTeX
@article{Buey2026,
author = {Buey, José Francisco Barbas del and García, Marcos Alonso and Martínez, Jesús Iñigo and Cofiño, Marta Elena Huerta and Montalvo, Mariel Morey and Bueno, Susana Jiménez and Arnáez, Araceli Arce},
title = {Change in respiratory syncytial virus disease burden toward the second year of life after nirsevimab immunization: insights from a two-year follow-up in a self-controlled case series study},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.1920752}
}
EUVIMED